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FK506 inhibits renal glomerular thrombosis induced in rats by
nephrotoxic serum and lipopolysaccharide
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FKSO6 inhibits renal glomerular thrombosis induced in rats by neph-
rotoxic serum and Iipopolysaccharide. We investigated the effect of the
potent immunosuppressive agent, FK506, on experimental glomerular
thrombosis in rats by combined injections of nephrotoxic serum (NTS)
and lipopolysaccharide (LPS). Either FK506 or placebo was adminis-
tered intramuscularly three hours prior to injection of NTS that was
followed one hour later by LPS. Rats were killed five hours alter the
LPS injection. Compared with placebo, FK506 pretreatment signifi-
cantly reduced thrombosis formation, in a dose-dependent manner.
FK506 also reduced proteinuria and the rise of serum creatinine level.
Early infiltration of polymorphonuclear leukocytes into the glomeruli
after LPS injection was significantly suppressed in the FK506 group
compared with the placebo group. We also measured serum tumor
necrosis factor (TNF) activity by using an L929 fibroblast cytotoxicity
assay. Peak serum TNF activity was observed one hour after LPS
injection, and FK506 significantly suppressed the elevation. Thrombo-
sis was also developed in athymic nude rats, suggesting thrombosis
formation is T cell independent. These data suggest that the FK506 has
inhibitory effects on non-lymphocytes and possesses an anti-inflamma-
tory effect in vivo.
Intraglomerular coagulation is important in the pathogenesis
and progression of renal lesions in both primary and secondary
renal diseases. Intraglomerular fibrin deposits are sometimes
seen in patients with primary glomerulonephritis, glomerulop-
athies associated with collagen disease, disseminated intravas-
cular coagulation, thrombotic thrombocytopenic purpura, ma-
lignant hypertension, preeclampsia and transplanted kidneys
[1—5].
We previously reported that experimental glomerular throm-
bosis could be induced in rats by administering nephrotoxic
serum (NTS) and lipopolysaccharide (LPS) in combination [6].
We consider this a modified model of Shwartzman reaction in
the kidney. NTS is used as a preparatory agent and LPS as a
provoking agent. The histological changes of this thrombosis
model resemble that of hemolytic uremic syndrome or severe
eclamptic nephropathy. Anticoagulant therapy with heparin or
warfarin could prevent glomerular thrombosis in this model [7].
FKSO6 is a macrolide isolated from Streptomyces tsukubaen-
sis [8]. It has potent immunosuppressive effects on lympho-
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cytes. It inhibits interleukin 2 (IL-2) production, gamma-inter-
feron production, IL-2 receptor expression, cytotoxic T cell
generation, and B cell activation [8—10]. Recently, effects of
FK506 on non-lymphocytes have been reported. It reduces
polymorphonuclear leukocytes (PMNs) motility on vitronectin
[11] and reduces the neutrophil infiltration in ischemialreperfu-
sion of feline small intestine [12].
We report that the immunosuppressive agent FK506 inhibits
NTS-LPS induced acute thrombosis in the kidney and explore
inhibitory mechanism.
Methods
Animals
Male Wistar rats weighing about 150 g were used in experi-
ments 1 to S. They had free access to food and water before the
experiments. One male and two female homozygous athymic
nude rats (mu/mu), five- to six-weeks-old weighing 70 to 90 g,
were obtained from Central Institute for Experimental Animals,
Kanagawa, Japan, and used in experiment 6. The nude rats
were derived from MRC Laboratory Animals Centre (Carshal-
ton, UK), and had been maintained at the Central Institute for
Experimental Animals. I lymphocyte function is almost defi-
cient in this nude rat [13, 14].
Treatment materials
Preparation of NTS and LPS. Rat glomerular basement
membrane was obtained from perfused renal cortices by the
method of Krakower and Greenspon [15]. The glomerular
basement membrane fraction was suspended in sterile physio-
logic saline solution at a concentration of 5 g/100 ml (wet wt).
Albino rabbits, each weighing 3 kg, were intraperitoneally
inoculated with 5 ml of the suspension four times at two week
intervals. Blood was drawn one week after the last injection.
Serum with nephrotoxic potency, which induced proteinuria in
rats 24 hours after the intravenous injection of 0.2 ml of
antiserum, was harvested and pooled. The pooled antiserum
was added with sodium azide to a final concentration of 0.1%,
inactivated at 56°C for 30 minutes, and stored at —20°C until
use. The LPS (TCA extract from Escherichia coil; Sigma
Chemical Co., St. Louis, Missouri, USA) was dissolved in
sterile physiologic saline solution in concentrations of 6 to 20
pg/ml and 0.5 ml of LPS-saline solution was administered
intravenously.
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by goat peroxidase anti-peroxidase (Cappel Research Prod-
ucts). Sections were then incubated with the peroxidase sub-
strate diaminobenzidine in 0.1 M Tris buffer containing 1 M
imidazole and 0.03% hydrogen peroxide. The sections were
rinsed in water and were lightly counterstained with hematox-
ylin. Twenty-five glomeruli on each section were counted under
light microscopy. The average number of positive cells in each
glomerular cross section in each animal was estimated (Fig.
2B).
Analyses of serum creatinine and urinary protein excretion
Serum creatinine was determined by automatic analyzer
(TBA2OR, Toshiba, Japan). The amount of urinary protein
excretion was measured by Bio-Rad Protein Assay (Bio-Rad
Laboratories, Richmond, California, USA) using bovine serum
albumin (Sigma Chemical Co.) as a standard.
Analyses of TNF activity
Fig. 2. Intraglomerular polymorphonuclear leukocyte (PMN) and ED-
I -positive cells. (A) An immunofluorescence photomicrograph of intra-
glomerular leukocytes stained with polycional anti-rat PMN antibody.
Increased numbers of PMN are present in the early phase of thrombosis
formation. (x400). (B) An immunohistochemical photomicrograph of
glomerular leukocytes stained with monoclonal anti-rat ED-i antibody.
Increased numbers of ED-I-positive cells are present after NTS injec-
tion (x300).
Enumeration of glomerular PMNs. Sections of frozen renal
cortex 3 m thick were fixed with paraformaldehyde-lysine-
periodate (PLP) and stained with FITC polyclonal anti-rat PMN
antibody (Inter-Cell Technologies Inc., Hopewell, New Jersey,
USA). Coverslips were mounted with phosphate-buffered sa-
line plus glycerol containing ethidium bromide (1 g/ml) to stain
nuclei. Twenty-five glomeruli on each section were counted
under epifluorescence microscopy. The average number of
positive cells in each glomerular cross section in each animal
was estimated (Fig. 2A).
Enumeration of ED-I positive cells. Sections of frozen renal
cortex 3 jsm thick were fixed with PLP and stained by the four
layers peroxidase anti-peroxidase method, as described by
Hancock and Atkins [16]. Briefly, sections were incubated with
optimally diluted mouse monoclonal anti-rat ED-i antibody
(Serotec Ltd., Oxford, UK), followed by goat anti-mouse IgG
(Cappel Research Products). ED-i is a marker of monocytes
and macrophages. After the sections were blocked with meth-
anol containing 0.03% hydrogen peroxide, they were incubated
with rabbit anti-goat IgG (Cappel Research Products), followed
TNF activity in rat serum was measured by the murine L929
fibroblast cytotoxicity assay based on the technique of Flick
and Gifford [17]. Briefly, L929 cells (Dainihon Laboratory
Products, Osaka, Japan) were suspended in RPMI-1640 con-
taining 5% fetal calf serum (FCS) and 1.0 x l0 cells were
plated in each well of 96-well flat bottom plates and incubated
for four hours at 37°C in a humidified atmosphere of 5% CO2 in
air. The culture medium was then discarded. Serum samples,
diluted ten times with RPMI-1640 medium containing 2.5% FCS
and 5 g/ml actinomycin D, were added in duplicate to L929
cells and incubated for 16 hours at 37°C in a humidified
atmosphere of 5% CO2 inair. Trays were then rinsed, fixed with
methanol, and stained with 1% crystal violet solution. Cytotox-
icity was indicated by the reduction in absorbance measured by
the ELISA reader (570 nm) and was expressed as ng/ml of TNF,
based on comparison with a standard curve using human
recombinant TNF-a (Genzyme, Cambridge, Massachusetts,
USA). The assay limit of TNF for the standard curve in our
study was 0.1 nglml. Because serum samples were diluted 10
times, the assay limit of the samples was 1 ng/ml.
Statistical analysis
Statistical significance was determined by the Wilcoxon rank
sum test. Values were expressed as the mean SD in the table
and figures.
Results
Experiment 1. Dose-response study of FK506 and
development of glomerular thrombosis
In the placebo group, the kidneys were markedly swollen and
appeared dark red and congested. Renal enlargement and
congestion were reduced in the FK506-treated group. Immuno-
fluorescent studies revealed diffuse, marked fibrin depositions
in the glomerular capillary walls in the placebo group. Throm-
bosis scores of the FKSO6 groups were significantly reduced
compared with the placebo group, in a dose-dependent manner
(Fig. 3).
Experiment 2. Effect of FK506 on proteinuria
The amount of urinary protein excretion was increased
markedly after NTS-LPS injections in the placebo group. This
300
200
0)
U)0
E2
-CI-
Placebo 0.1 1
FK506, mg/kg
Fig. 3. Development of glomerular thrombosis in a dose-response
study of FK506. Rats were administered placebo or FK506 intramus-
cularly. Three hours later, they were injected with 0. 14 ml nephrotoxic
serum and 3 pg lipopolysaccharide at one hour intervals. The highest
possible thrombosis score is 250. Data represent mean SD (five
rats/group). *P< 0.05 vs. placebo group; < 0.01 vs. placebo group.
Drug
Proteinuna ,ng/5 hr
Thrombosis scorePrea After LPSb
Placebo (N = 5) 0.53 0.35 12.25 8.01 194 55
FK506 10 mg/kg 0,37 0.12 2.73 3.66c 47 55d
(N = 5)
increase was significantly suppressed in the FK506 group
(Table 1).
Experiment 3. Comparison of timing of FK506 administration
Rats administered FK506 either before or after the NTS
injection showed significant suppression of thrombosis scores
compared with rats in the placebo group. There was no signif-
icant difference between the two FKSO6-treated groups (Fig. 4).
Experiment 4. Course following LPS injection
Fibrin depositions appeared in glomerular sections one hour
after LPS injection and increased gradually in both the placebo
and the FKSO6 groups. Thrombosis scores of the FK506 group
two hours and five hours after LPS injection were significantly
reduced compared with those of the placebo group (Fig. 5A).
The serum creatinine level rose five hours after LPS injection in
the placebo group but not in the FK506 group (Fig. SB).
Peripheral WBC and PMN counts decreased 30 minutes after
LPS injection in the placebo group. This decline was signifi-
cantly suppressed in the FK506 group (Fig. 6). One hour after
the LPS injection both groups showed decreases in peripheral
WBC and PMN counts compared with the LPS (—) group. No
significant difference was seen between the FK506 and the
placebo group.
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Fig. 4. Thrombosis scores when FK506 was administered before or
after nephrotoxic serum (NTS). Rats were injected with 0.14 ml NTS
and 10 pg lipopolysacchanide at eight hour intervals. FK506 10 mg/kg
was administered either three hours before or four hours after the NTS
injection. Placebo was administered four hours after NTS. The highest
possible thrombosis score is 250. Data represent mean SD (5
rats/group). P < 0.01 vs. placebo group. NS is not significant.
The number of intraglomerular PMNs was elevated one hour
after NTS injection, just before the LPS injection (time 0 in Fig.
7A), but there was no significant difference between the FK506
and the placebo groups. A dramatic increase was observed 30
minutes and one hour after LPS injection in the placebo group.
Although both groups showed so much infiltration of PMNs in
glomeruli two hours after the LPS injection, the early infiltra-
tion was significantly suppressed in the FK506 group. The
number of intraglomerular ED-i-positive cells was markedly
elevated one hour after NTS injection (Fig. 7B). The ED-l-
positive cell count was decreased after LPS injection in both the
FK506 and the placebo groups compared with the LPS (—)
group. There was no significant difference between the FK506
and the placebo group at any time.
Peak TNF activity was observed one hour after the LPS
injection. FK506 significantly suppressed TNF activity 30 min-
utes and one hour after LPS injection (Fig. 8A).
Experiment 5. Serum TNF activity after LPS injection
without NTS
TNF activity was also suppressed by FKSO6 one hour after
LPS injection in rats not previously injected with NTS (Fig.
8B).
Experiment 6. Development of thrombosis in nude rats
All nude rats showed marked thrombosis formation. Throm-
bosis scores of each nude rat that received 1, 1, 5 pg of LPS
were 232, 240, and 216, respectively.
Discussion
Many studies have investigated the immunosuppressive ef-
fects of FK506. In vitro experiments demonstrated that FK506
inhibits IL-2 production, gamma-interferon production, IL-2
receptor expression, cytotoxic T cell generation, and B cell
activation [8—10]. In vivo studies demonstrated marked immu-
nosuppressive notencv in allotransolantation of the kidney.
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Table 1. Effect of FK506 on proteinuria induced by NTS-LPS
administration
Data are expressed as the mean 5D.
a Five hours urine collection without any treatment
b Five hours urine collection after LPS administration
P < 0.05 vs. placebo groupd P < 0.01 vs. placebo group
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Fig. 5. Sequential thrombosis scores (A) and serum creatinine levels
(B) after injection of lipopolysaccharide (LPS). Three hours after rats
were administered 10 mg/kg FK506 () or placebo (•) intramuscularly,
they were injected with 0.14 ml nephrotoxic serum and 3 g LPS at one
hour interval. Data represent mean SD (5 rats/group); * < 0.01 vs.
placebo group.
liver, and heart in both human and animal models [18—22].
FK506 also has strong inhibitory effects on development of
experimental collagen arthritis, autoimmune uveoretinitis, ac-
celerated nephrotoxic serum glomerulonephritis, and Hey-
mann's nephritis [23—26]. These actions are thought to be
related to the inhibitory effects of FK506 on lymphocytes. As
glomerular thrombosis was also developed in T cell-deficient
nude rats, lymphocytes do not seem to play an important role in
our thrombosis model. Recently, the effects on non-lympho-
cytes have been reported. FK506 inhibits PMN degranulation
induced by either calcium ionophore or ionomycin [27], reduces
PMN motility on vitronectin [11], and reduces the neutrophil
infiltration induced by reperfusion of the ischemic small intes-
tine in cats [12]. FK506 also inhibits histamine release and de
novo synthesis of 5-lipoxygenase and cyclo-oxygenase metab-
olites of arachidonic acid from lung parenchymal mast cells
activated by anti-IgE [28]. Pretreatment by FK506 was reported
to ameliorate the acute renal injury associated with ischemial
reperfusion and to inhibit TNF production [29].
In the NTS-LPS induced thrombosis model or Shwartzman
reaction, PMNs are considered to be important in tissue injury
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Fig. 6. Sequential peripheral white blood cell (WBC) count (A) and
polymorphonuclear leukocyte (PMN) count (B) after injection of lipo-
polysaccharide (LPS). Rats were treated as in Figure 5. To eliminate
the influence of LPS, other rats pretreated with placebo () were
injected with 0.14 ml nephrotoxic serum and killed 2 hours later [LPS
(—) group]. Symbols are: (•) placebo; (0) FK506; (is) LPS (—). Data
represent mean SD (5 rats/group). *D< 0.06 vs. placebo group.
<0.01 vs. placebo group. *P < 0.05 vs. LPS (—) group. *P < 0.01 vs.
LPS (—) group.
[6, 30, 31]. A leukocytopenic state (less than 600 leukocytes/4)
induced by the pre-administration of cyclophosphamide pre-
vented the development of glomerular thrombosis in the NTS-
LPS model, and it was restored by the transfusion of normal
PMNs into these animals [6]. Prominent infiltration of PMNs in
glomeruli was observed in the course of thrombosis formation.
Electron microscopic examination revealed that endothelial
cells were stripped off, and many PMNs directly attached to the
glomerular basement membrane after LPS injection (unpub-
lished observation). The infiltrating cells would release toxic
granule components or generate reactive oxygen metabolites,
which would damage the tissue and lead to blood coagulation.
The peripheral leukocyte counts did not differ in the placebo
and the FK506 groups before NTS injection in our experiment.
The amount of peripheral PMNs would be enough to produce
thrombosis in the FK506-pretreated rats. It is interesting that
the early decrease of peripheral PMN counts and the accumu-
lation of PMNs into the glomeruli were prevented by FK506. As
moderate fibrin depositions have already been observed two
hours after LPS injection in the placebo group, the inhibition of
early infiltration of PMNs into glomeruli by FK506 would be
G0
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Fig. 7. Sequential intraglomerular polymorphonuclear leukocyte
(PMN) count (A) and ED-I-positive cell count (B) after injection of
lipopolysaccharide (LPS). Symbols are: (U) placebo; () FK506; (liii)
LPS (—). Rats were treated as in Fig. 6. Data represent mean SD (5
rats/group). *D < 0.01 vs. placebo group; **P < 0.05 vs. placebo group;
*p < 0.01 vs. LPS (—) group.
important to prevent glomerular thrombosis. We suppose that
changes of peripheral and intraglomerular PMN counts would
be affected by mediators such as complements, cytokines, and
adherent molecules. Though we did not estimate whether the
difference of PMN counts between the placebo and FK506
group is the direct effect of FK506 on PMNs or via suppression
of those mediators, these findings seem to correspond with the
reported ability of FKSO6 to reduce PMN motility on vitronec-
tin in vitro [11] and to reduce PMNs infiltration induced by
reperfusion of the ischemic small intestine in vivo [12].
TNF is a cytokine produced by activated macrophages and
monocytes detectable in the circulation of experimental animals
given endotoxin [32]. It is considered to be one of the principal
mediators of the lethal effect of endotoxin. Mice passively
immunized with antiserum directed against TNF are protected
against endotoxin [33]. Rabbits given massive doses of human
recombinant TNF show glomerular damage, with PMNs accu-
mulation and fibrin formation similar to those found in animals
Time after LPS injection, hours
Fig. 8. Sequential serum tumor necrosis factor (TNF) activity after
injection of lipopolysaccharide (LPS) in rats pretreated with nephro-
toxic serum (NTS) in experiment 4 (A) and in rats not given NTS in
experiment 5 (B). Symbols are: (U) placebo; (0) FK506. Data represent
mean SD (5 rats/group). p < 0.01 vs. placebo group; < 0.05 vs.
placebo group.
given endotoxin [32]. Pretreatment with TNF increases albu-
minuria and the prevalence of glomerular capillary thrombi in
nephrotoxic serum glomerulonephritis [34]. In vitro study has
shown that human recombinant TNF acts directly on human
vascular endothelium to induce tissue factor-like procoagulant
activity [35]. In clinical cases, TNF is produced in situ by
activated infiltrating mononuclear cells in anti-neutrophil cyto-
plasmic antibody (ANCA) positive glomerulonephritis [36].
Thus, TNF is an important mediator of inflammation and
coagulation in vivo and in vitro. The suppression of serum TNF
activity by FK506 would be important to reduce glomerular
thrombosis in this model.
ED-i is the marker of macrophages and monocytes. Infiltra-
tion of ED-i-positive cells was observed one hour after NTS
injection, just before LPS injection. Not only the increase of
serum TNF level after LPS injection, but also the local TNF
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secretion from those infiltrating cells in glomeruli would con-
tribute to the glomerular damage. The reason why ED-i-
positive cells decreased after LPS injection, unlike the accumu-
lation of PMNs, is unknown. Though FK506 seems to have
little influence of macrophages/monocytes traffic in giomeruli,
there is a possibility that FK506 also suppresses local TNF
secretion from those cells.
Recently TNF has been reported to be produced by glomer-
ular mesangial cells. The mRNA encoding TNF-a is expressed
by mesangial cells after LPS stimulation, and TNF activity is
increased in the culture medium [37]. In vivo, administration of
LPS also results in glomerular TNF-a mRNA expression and
bioactivity in the absence of leukocyte infiltration [38]. Mesan-
gial cells as well as monocytes would contribute to the local
TNF production in the kidney in this thrombosis model and
have a role in generating thrombosis formation.
FK506 inhibits T lymphocyte activation genes such as IL-2,
IL-3, IL-4, granulocyte-macrophage colony stimulating factor,
interferon gamma, and TNF [39]. In the case of monocytes,
which are considered to be the major source of TNF produc-
tion, FKSO6 and cyclosporin A inhibit Staphylococcus aureus
enterotoxin A or calcium ionophore induced-TNF production,
but not LPS-induced TNF production [40]. Andersson et al [40]
studied TNF production at a single-cell level by ultraviolet
microscopy using cytokine-specific monoclonal antibody. Al-
though their findings seem to be inconsistent with our data,
their examination was in vitro, and the secreted TNF bioactiv-
ity was not measured. Cyclosporin A and FK506 achieve
immunosuppression via inhibition of calcineurin [41]. Cyclo-
sporin A inhibits LPS-induced secreted TNF bioactivity of
macrophages [42]. However, no suppression of TNF mRNA
and accumulation of cell-associated TNF was observed. There
is a possibility that FKSO6 suppresses the secretion of TNF
from monocytes/macrophages but not the accumulation of TNF
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